The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy - PubMed
4 hours ago
- #immunotherapy
- #hepatocellular carcinoma
- #prognostic marker
- The study evaluates the Advanced Lung Cancer Inflammation Index (ALI) as a prognostic indicator in patients with unresectable hepatocellular carcinoma (u-HCC) treated with atezolizumab plus bevacizumab (Atez/Bev).
- A retrospective analysis of 563 u-HCC patients treated with Atez/Bev (Sept 2020-Dec 2024) was conducted, calculating ALI based on BMI, serum albumin, and neutrophil-to-lymphocyte ratio.
- Patients were divided into low- and high-ALI groups using a cutoff of 27.04. High-ALI patients showed significantly better median overall survival (26.1 vs. 13.7 months) and progression-free survival (9.3 vs. 5.2 months).
- High-ALI patients also had a higher disease control rate (82.5% vs. 69.1%) compared to low-ALI patients.
- Multivariate analysis confirmed high ALI as a significant prognostic marker for improved OS (HR 0.69) and PFS (HR 0.75).
- Subgroup analyses consistently supported better outcomes for high ALI across all clinically relevant subgroups.
- The study concludes that high pretreatment ALI is associated with improved survival and disease control in u-HCC patients on Atez/Bev, suggesting its utility as a prognostic marker.